Full Text View
Tabular View
No Study Results Posted
Related Studies
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors (D-1MT)
This study has been terminated.
( Lack of enrollment. )
Study NCT00739609   Information provided by NewLink Genetics Corporation

First Received on August 20, 2008.   Last Updated on January 8, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Lung Cancer
Melanoma
Pancreatic Cancer
Solid Tumors
Additional conditions recognized in this trial
Breast Neoplasms
Lung Neoplasms
Neoplasms
Pancreatic Neoplasms
More general conditions related to this trial
Breast Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Lung Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Pancreatic Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Interventions listed in this trial
1-methyl-D-tryptophan
Additional drug interventions recognized in this trial
Tryptophan
More general drug interventions related to this trial
Antidepressive Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Pharmacologic Actions
Psychotropic Drugs
Therapeutic Uses
Sponsors listed in this trial
NewLink Genetics Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services